Cirius Therapeutics

General Information
Business:

 

We are a clinical-stage pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and metabolic diseases. Our lead product candidate, MSDC-0602K, is a novel, once-daily, oral small molecule being developed to treat nonalcoholic steatohepatitis, or NASH, with fibrosis. MSDC-0602K selectively modulates the mitochondrial pyruvate carrier, or MPC, which mediates at the cellular level the effects of overnutrition, a major cause of NASH and other metabolic disorders. We are conducting a Phase 2b clinical trial of MSDC-0602K, which we have fully enrolled with 402 patients diagnosed with NASH with fibrosis.

Industry: Health Care
Employees: 11
Founded: 201
Contact Information
Address 12651 High Bluff Drive, Suite 150, San Diego, CA 92130,
Phone Number (858) 333-6274
Web Address http://www.ciriustx.com
View Prospectus: Cirius Therapeutics
Financial Information
Market Cap
Revenues $0 mil (last 12 months)
Net Income $-22.4 mil (last 12 months)
IPO Profile
Symbol CSTX
Exchange NASDAQ
Shares (millions): 0.0
Price range $0.00 - $0.00
Est. $ Volume $86.3 mil
Manager / Joint Managers Citigroup/ Credit Suisse
CO-Managers Needham & Company/ Wedbush PacGrow
Expected To Trade:
Status: TBA
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change